| Document |
Document Title |
|
WO/1985/005107 |
Crystalline anhydrides, hemihydrates, monohydrates or trihydrates of (6R, 7R)-7- AD(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido BD-3-(1-quinuclidiniummethyl)-3-cephem-4-carboxylate or derivatives thereof.
|
|
WO/1985/005106 |
Novel cephem compounds of general formula (I), wherein R1 represents an optionally protected amino group, R2 represents a hydrogen atom or a halogen atom, R3 represents a hydrogen atom or an optionally substituted hydrocarbon residue, R4...
|
|
WO/1985/004879 |
Novel cephem compounds of general formula (I), wherein R1 represents and optionally amino group, R2 represents H or halogen, R3 represents H or an optionally substituted hydrocarbon residue, R4 represents H or methoxy, A represents an op...
|
|
WO/1985/004878 |
Compounds of general formula (I), their pharmaceutically acceptable salts and in-vivo hydrolysable esters are antibacterial agents; in which R1 is optionally substituted phenyl or optionally substituted 5 or 6-membered heterocyclyl; R2 i...
|
|
WO/1985/004659 |
Process for preparing intermediary products of cephalosporine having the formula (I) wherein R1 is an acyl group. Modification of a compound having the formula (IV) and/or (IVa) wherein R1 has the same meaning as hereabove and (A), respe...
|
|
WO/1985/004404 |
A process for the preparation of compounds of formula (I), wherein R1 represents hydrogen or a hydroxy-protecting group, R2 represents hydrogen, a cation, the pivaloyloxymethyl group or a carboxy-protecting group and R3 represents hydrog...
|
|
WO/1985/003938 |
Cephalosporin derivatives represented by formula (I), (wherein R1 represents a hydrogen atom or a protective group, R2 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl grou...
|
|
WO/1985/003937 |
The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are compounds of the formula (I), and the non-toxic pharmaceutically acceptable salts thereof, wherein D is ...
|
|
WO/1985/001046 |
Mandelic acid derivatives represented by general formula (I), wherein R1 represents a hydrogen atom or a hydroxy group, X represents a halogen atom or OR2 (wherein R2 represents a hydrogen atom, benzyl, benzhydryl, t-butyl, tetrahydropyr...
|
|
WO/1984/004747 |
Cephem compounds represented by general formula (I), wherein R1 represents a hydrogen atom or an amino group-protecting group and R2 represents formula (II) or (III), wherein R3 represents a lower alkyl group and R4 represents a lower al...
|
|
WO/1984/004096 |
Novel compounds of formula (I), a process for their preparation, pharmaceutical compositions containing the same as active ingredient and their use in therapy as antibiotics. The compounds of the formula (I) according to the invention st...
|
|
WO/1984/002911 |
A compound of formula (I) or a salt thereof, wherein R1 and R3 are independently an in vivo hydrolysable group, or R1 and R3 together form an in vivo hydrolysable group, provided that R1 and R3 are not both C1-6 alkylcarbonyl; R7 is a hy...
|
|
WO/1984/002703 |
A process for preparing novel aminothiazolylacetic acid derivatives useful as intermediates for synthesizing beta-lactam antibiotics, starting with diketene as shown in formula (I), wherein R represents lower alkyl or phenyl, R1 and R2 e...
|
|
WO/1984/001949 |
Cephalosporin derivatives represented by the general formula (I), wherein R1 represents an alpha-, beta- or gamma-amino acid residue (bonded through an ester bond) whose amino group is optionally susbstituted by a lower alkyl group, R2 r...
|
|
WO/1984/001950 |
Cephalosporin derivatives represented by formula (I) (wherein R represents -CH2-OCORa1 (wherein Ra1 represents an alkyl group),$(4,)$(wherein Rb1 represents an alkyl group),$(4,)$(wherein Rc1 represents an alkyl group),$(6,)$or phthalidy...
|
|
WO/1984/001152 |
Azetidinone compounds represented by the general formula (I), wherein R1 represents a substituted or unsubstituted phenyl group, R2 represents a carboxyl-protecting group, X represents a hydrogen atom or a chlorine atom, Y represents$(7,...
|
|
WO/1984/000965 |
2-Substituted cephem derivatives represented by the general formula (I), (wherein R1 represents substituted or unsubstituted phenyl, substituted or unsubstituted phenylmethyl, or substituted or unsubstituted phenoxymethyl, R2 represents ...
|
|
WO/1984/000964 |
Cephalosporin compounds represented by the general formula (I), wherein R1 represents alkyl, alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylmethyl, or substituted or unsubstituted phenoxymethyl, and R2 repre...
|
|
WO/1983/003968 |
The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are: (a) compounds of the formula: ADD-DHC BD (I), wherein ADD BD is a centrally acting drug species, and AD...
|
|
WO/1982/001004 |
A process for preparing cephalosporin compounds represented by the following general formula (III): (FORMULA) (wherein R represents a hydrogen atom or a methyl group) or the pharmaceutically acceptable salts thereof, which comprises reac...
|
|
WO/1980/000337 |
A primary alcohol or an aldehyde is reacted with ammonia or a primary or secondary amine together with a molecular oxygen-containing gas in the presence of a palladium or platinum catalyst under oxidative condition to prepare a correspon...
|
|
JP2011063616 |
To provide a process for producing 7-amino-3-[2-(4-methylthiazol-5-yl)vinyl]-3-cephem-4-carboxy
lic acid or its salt having a high Z-isomer content and a low content of phenylacetic acid or its derivative as an impurity.Enzymatic reactio...
|
|
JP2010254697 |
To provide a new antibiotic highly effective against antibiotic-resistant bacterial strains.There are provided a crossrinked glycopeptide-cephalosporin compound and a pharmaceutically acceptable salt thereof which are useful as antibioti...
|
|
JP2010184925 |
To provide a new crystalline form of cefdinir having higher stability and lower solubility than the well-known crystalline form of cefdinir.The new crystalline form of cefdinir having specific X-ray diffraction spectra is obtained by the...
|
|
JP2010119382 |
To provide a method for fluorescently labeling a protein labeling in vivo molecules.The method for fluorescently labeling the protein includes to obtain a fused protein of a target protein with a variant -lactamase and to fluorescently l...
|
|
JP2010077115 |
To provide a method for selectively producing Z isomer of a cephem compound useful as a synthetic intermediate for a cephalosporin antibiotic substance in high yield.A 3-[2-(4-methylthiazol-5-yl)vinyl]-3-cephem compound (A) expressed by ...
|
|
JP2010024148 |
To further increase the content of a Z isomer compared to an E isomer in the manufacture of 7-amino-3-[(E/Z)-2-(4-methylthiazol-5-yl)vinyl]-3-cephem-4-c
arboxylic acid or an alkali salt thereof.The content of 7-amino-3-[(Z)-2-(4-methylth...
|
|
JP2009249380 |
To provide a new intermediate compound effectively usable in producing cefdinir, and a method for effectively producing the cefdinir using the same.Provided is the method for producing a cefdinir of general formula (7) characterized by c...
|
|
JP2009143962 |
To provide cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof, which are useful as antibiotics.Pharmaceutical compositions containing the compounds, methods for treating bacterial infections i...
|
|
JP2009114202 |
To provide a new cephem compound having excellent antimicrobial action, stability and oral absorption property, to provide a method for producing the compound, and to provide an agent containing the compound.The present invention provide...
|
|
JP2009040795 |
To provide cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics.The invention also provides pharmaceutical compositions containing such compounds, methods for tre...
|
|
JP2008189688 |
To provide a crystalline acid-addition salt from cefdinir; to provide a production method of the acid-addition salt; and to provide a cefdinir production method using the acid-addition salt.High purity cefdinir can be produced by a metho...
|
|
JP2007131535 |
To provide an agent for suppressing the formation of a modified protein, free from hypotensive action and inducing no vitamin B6 deficiency.The agent for suppressing the formation of a modified protein uses a compound having a free or sa...
|
|
JP2007119484 |
To provide a new antibacterial agent of cephem compound expressing a wide antibacterial spectrum to various pathogenic bacteria.The compound is expressed by formula (I), wherein Acyl expresses an acyl applicable to the β-lactam field; T...
|
|
JP2007106684 |
To provide a pharmaceutical preparation containing cefditoren pivoxil, having improved wettability with water and improved dissolution property and exhibiting high initial dissolution rate.The pharmaceutical composition comprises 0.1-10 ...
|
|
JP2007077137 |
To provide an industrial method for directly converting cefepime being a cephalosporin having a wide action spectrum into sterilized cefepime dihydrochloride monohydrate.The method for producing sterilized cefepime dihydrochloride monohy...
|
|
JP2007077123 |
To provide a cefdinir which solves a problem that conventional crystalline cefdinir is slightly soluble in water, and has high solubility in water.The present invention relates to amorphous cefdinir which does not contain crystalline cef...
|
|
JP3927262 |
To produce a specific new cephem compound capable of manifesting excellent antimicrobial activities against Gram-positive and Gram-negative bacteria including methicillin-resistant Staphylococcus aureus(MRSA) and useful as an antimicrobi...
|
|
JP3920939 |
To obtain a new crystalline cephem acid addition salt with long half- life in the blood and excellent medicinal sustainability, useful for the treatment of bacterial infectious diseases. This compound is shown by formula I [(n) is 1 or 2...
|
|
JP3914276 |
To obtain a specific new cephalosporin derivative having a substituted sulfonylmethyl group bonded to the 3-site of cephem ring, having a broad antibacterial spectrum and strong antibacterial action and useful for an antibacterial agent,...
|
|
JP2007023046 |
To provide new cepham compounds having antimicrobial activities, their production method, intermediates and a pharmaceutical composition containing the cepham compounds.The antibacterial compounds are expressed by formula I [in the formu...
|
|
JP3868008 |
PURPOSE: To obtain a new temp. and moisture stable compd. useful as a compsn. for injection. CONSTITUTION: This dihydrate of 7-[α-(2-aminothiazol-4-yl)-α-(Z)- methoxyiminoacetamide)-3-[(1-methyl-1-pyrrolidino)methyl]-3-
cephem-4- carbo...
|
|
JP3856807 |
To provide a beta-lactamase as a reporter gene, a beta-lactamase substrate compound and uses thereof for particularly monitoring expression from a pair of expression control sequences to screen a biochemical activity. Disclosed is a reco...
|
|
JP3850692 |
To provide a method of preparing a cephalosporin compound and an intermediate for preparation of these compound. This method cyclizes a compound of formula (III) to obtain a compound expressed by formula (II). [R1 is H, a methoxy or form...
|
|
JP3837439 |
To obtain a new cephem compound having an excellent antibacterial power, especially exhibiting a storing antibacterial activity against MRSA, high in solubility in water, low in toxicity and high in safety. For this cephen compound, a ce...
|
|
JP2006206529 |
To provide a method for producing a compound represented by formula (1).The compound represented by formula (2) and its salts are found out as efficient synthetic intermediates of the above-mentioned compound. [Wherein, R is H, an alkyl ...
|
|
JP3791941 |
PURPOSE: To obtain the subject high-purity compound important as an intermediate for cephem-based antibiotic substances useful as an oral agent in high yield according to safe and simple operations by using a specific arenyl β-lactam co...
|
|
JP2006096679 |
To provide a new inexpensive manufacturing method of cefditoren.The manufacturing method of 7-[2-methoxyimino-2-(2-aminothiazol-4-yl)acetamide]-3-[2-(4-
methylthiazol-5-yl)vinyl]-3-cefem-4-carboxylic acid (cefditoren) represented by form...
|
|
JP3775819 |
PURPOSE: To obtain the subject high-purity compound useful as an antimicrobial agent having a wide range of antimicrobial spectra in high yield according to simple operations by using a specific halomethylcephem compound as a starting ra...
|
|
JP3775836 |
To safely and easily produce a compound useful as a production intermediate for cephem antibiotics for oral administration in high yield and purity by reacting a specific allenyl β-lactam compound with a halogenation reagent in the pres...
|
